Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ÈÄ°¢½Å°æ¾Æ¼¼Æ÷Á¾ÀÇ Ä¡·á ¹× °á°ú Treatment and Results of Olfactory Neuroblastoma

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2000³â 18±Ç 3È£ p.177 ~ 181
¿ìÈ«±Õ, ±èÀÏÇÑ,
¼Ò¼Ó »ó¼¼Á¤º¸
¿ìÈ«±Õ (  ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ÈäºÎ¿Ü°úÇб³½Ç

±èÀÏÇÑ (  ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ÈäºÎ¿Ü°úÇб³½Ç

Abstract

¸ñ Àû :ÈÄ°¢½Å°æ¾Æ¼¼Æ÷Á¾Àº ¸Å¿ì µå¹°°í Ä¡·á ¹æ¹ýÀÇ °áÁ¤ÀÌ ¾î·Á¿î Á¾¾çÀÌ´Ù . ÀÌ ¿¬±¸¿¡¼­´Â º» º´¿ø¿¡¼­ ½ÃÇàÇÑ ÈÄ°¢½Å°æ¾Æ¼¼Æ÷Á¾ÀÇ ¿©·¯ °¡Áö Ä¡·á¹æ¹ýÀ» Á¤¸®ÇÏ°í ÃÖ±Ù¿¡ ¹ßÇ¥µÈ ¹®ÇåµéÀ» °íÂûÇÏ°íÀÚ ÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý :1979 ³â 6 ¿ùºÎÅÍ 1997 ³â 4 ¿ù »çÀÌ¿¡ ¼­¿ï´ëÇб³º´¿ø¿¡¼­ ÈÄ°¢½Å°æ¾Æ¼¼Æ÷Á¾À¸·Î Áø´ÜÀ» ¹Þ°í Ä¡·á¸¦ ¹ÞÀº 20 ¸íÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÇÏ¿´´Ù . 14 ¸íÀÇ ³²ÀÚ¿Í 6 ¸íÀÇ ¿©ÀÚ°¡ Æ÷ÇԵǾú´Ù. ÃÖÃÊ Áø´Ü ½Ã ¿¬·ÉÀº 13 ¼¼ºÎÅÍ 77 ¼¼±îÁö¿´À¸¸ç Áß¾Ó°ªÀº 24
¼¼¿´´Ù
. 20 ¸íÁß 14 ¸íÀº Kadish º´±â C ¿´´Ù . ȯÀÚ °³°³Àο¡ µû¶ó¼­ ¼ö¼ú°ú ¹æ»ç¼±Ä¡·á , Ç×¾ÏÈ­Çпä¹ýÀÇ ´Ù¾çÇÑ Á¶ÇÕÀÌ ½ÃÇàµÇ¾ú´Ù . ÀÌ·¯ÇÑ Á¶ÇÕÀ¸·Î´Â ¼ö¼ú°ú ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·á ¹× ¼ö¼ú ÈÄ Ç×¾ÏÈ­Çпä¹ý 2 ¿¹ , ¼ö¼ú°ú ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·á 6 ¿¹ , ¼ö¼úÀü
Ç×¾ÏÈ­Çпä¹ý°ú
¼ö¼ú 1 ¿¹ , ¼ö¼ú°ú ¼ö¼ú ÈÄ Ç×¾ÏÈ­Çпä¹ý 1 ¿¹ , ¼ö¼ú ´Üµ¶¸¸ ½ÃÇà 2 ¿¹ , ¹æ»ç¼±Ä¡·áÀü È­Çпä¹ý°ú ¹æ»ç¼±Ä¡·á 3 ¿¹ , ¹æ»ç¼±Ä¡·á ¹× ¹æ»ç¼±Ä¡·á ÈÄ Ç×¾ÏÈ­Çпä¹ý 1 ¿¹ , ¹æ»ç¼±Ä¡·á ´Üµ¶ 3 ¿¹ , ¸ðµç Ä¡·á¸¦ °ÅºÎÇÑ 1 ¿¹°¡ Æ÷ÇԵǾú´Ù .
°á °ú :ÃßÀû ±â°£Àº 2 °³¿ùºÎÅÍ 204 °³¿ù»çÀÌ·Î Áß¾Ó°ªÀº 40 °³¿ùÀ̾ú´Ù . 5 ³â »ýÁ¸À²°ú 10 ³â »ýÁ¸À²Àº °¢°¢ 20%¿Í 10%¿´´Ù . 4 ¸íÀÇ È¯ÀÚ°¡ ÀÚ·á ºÐ¼®ÀÇ ½ÃÁ¡±îÁö »ýÁ¸ÇØ ÀÖ¾úÀ¸¸ç ÀÌ 4 ¸íÁß ÇѸíÀº ±ÙÄ¡Àû ¼ö¼ú°ú ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·á ¹× ¼ö¼ú ÈÄ
Ç×¾ÏÈ­Çпä¹ýÀ¸·Î
Ä¡·á¸¦ ¹Þ¾ÒÀ¸¸ç 2 ¸íÀº ±ÙÄ¡Àû ¼ö¼ú°ú ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·á , ±×¸®°í ³ª¸ÓÁö ÇѸíÀº ±ÙÄ¡Àû ¼ö¼ú¸¸ ½ÃÇà¹Þ¾Ò´Ù .
°á ·Ð :ÈÄ°¢½Å°æ¾Æ¼¼Æ÷Á¾ÀÇ Ä¡·á¿¡´Â ù Áø´Ü ½Ã¿¡ ±ÙÄ¡Àû ¼ö¼ú°ú ¼ö¼ú Àü ¶Ç´Â ¼ö¼ú ÈÄ º¸Á¶Àû ¹æ»ç¼±Ä¡·á¿Í Ç×¾ÏÈ­Çпä¹ýÀ» º´¿ëÇÏ´Â Á¢±ÙÀÌ ÇÊ¿äÇÒ °ÍÀÌ´Ù . ȯÀÚ¼ö°¡ ÀûÀº Á¦ÇÑÀÌ ÀÖÀ¸³ª º» ¿¬±¸¿¡¼­´Â ±ÙÄ¡Àû ¼ö¼ú µî ±¹¼ÒÁ¶ÀýÀÇ Á߿伺ÀÌ °­Á¶µÇ¾ú´Ù .

Purpose : Rarity of olfactory neuroblastoma makes it difficult for treating physician to practice with a consistent
protocol. This study is performed to analyze our experience with various treatment modalities for patients with
olfactory neuroblastoma. Discussion includes review of some recently published literatures.
Methods and Materials : Between June of 1979 and April of 1997, 20 patients were treated under the diagnosis
of olfactory neuroblastoma at Seoul National University Hospital. There were 14 male and 6 female patients. Age
at initial treatment ranged from 13 to 77 years with median of 24 years. Fifteen of 20 patients had Kadish stage C.
They were treated with various combinations of surgery, radiation therapy and chemotherapy; surgery £«
postoperative radiation therapy £«adjuvant chemotherapy for 2 patients, surgery £«postoperative radiation therapy
for 6, neoadjuvant chemotherapy £«surgery for 1, surgery £«adjuvant chemotherapy for 1, surgery only for 2,
neoadjuvant chemotherapy £«radiation therapy for 3, radiation therapy £«adjuvant chemotherapy for 1, radiation
therapy only for 3, and no treatment for 1 patient.
Results : Follow-up ranged from 2 month to 204 months with mean of 39.6 months. The overall 5- and 10-year
survival rates are 20% and 10%, respectably. Four patients are alive at the time of data analysis. One of four living
patients was treated with radical surgery, postoperative radiation therapy and adjuvant chemotherapy, two patients
with radical surgery and postoperative radiation therapy, and one with radical surgery only.
Conclusion : Multidisciplinary approach, including radical surgery, pre- or post-operative radiation therapy and
chemotherapy, should be addressed at the initial time of diagnosis. Although limited by small number of the
patients, this study suggests importance of local treatment modality, especially radical surgery in the treatment of
olfactory neuroblastoma.

Å°¿öµå

ÈÄ°¢½Å°æ¾Æ¼¼Æ÷Á¾; ¼ö¼ú; ¹æ»ç¼±Ä¡·á; Ç×¾ÏÈ­Çпä¹ý; Olfactory neuroblastoma; Surgery; Radiation therapy; Chemotherapy;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS